Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT03962543
Title MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas (ReNeu)
Acronym ReNeu
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors SpringWorks Therapeutics, Inc.
Age Groups: senior | child | adult
Covered Countries USA

No variant requirements are available.